News - OxyDial Inc

Sep 27 2024

Luspatercept Outperforms Epoetin Alfa in Phase III COMMANDS Trial for MDS Anemia

The phase III COMMANDS trial has revealed a massive development in treating myelodysplastic syndromes (MDS). According to the primary analysis, Luspatercept, developed by Acceleron Pharma, demonstrated superior efficacy to epoetin …

OxyDial

Sep 23 2024

New Agios Pharma MDS Treatment Gains FDA ‘Orphan Drug’ Status

Agios Pharmaceuticals has reached a significant milestone in the development of their new myelodysplastic syndrome (MDS) treatment, Tebapivat, with the FDA’s recent designation of the drug as an ‘orphan drug’. …

OxyDial

Sep 13 2024

Novo Nordisk Advances Etavopivat to Phase III Trial for Sickle Cell Disease

Novo Nordisk has received Subject Expert Committee (SEC) approval from India’s Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trials of etavopivat in the treatment of sickle …

OxyDial

Sep 6 2024

Merck Advances Bomedemstat in Phase III Trial for Essential Thrombocythemia

Pharmaceutical giant Merck has announced the start of the Phase III Shorespan-007 trial to evaluate bomedemstat (MK-3543) in approximately 300 essential thrombocythemia (ET) patients globally. The study is set to …

OxyDial

Aug 30 2024

Earlier Treatment with Luspatercept May Improve Patient Outcomes

New data from the ongoing COMMANDS trial shows Bristol Myers Squibb‘s new myelodysplastic syndrome (MDS) drug, Luspatercept (Reblozyl) may significantly improve anemia in low-risk patients with MDS. The Director of …

OxyDial

Aug 23 2024

Agios Pharmaceuticals Advances Therapies for Rare Blood Disorders

Agios Pharmaceuticals continues to make remarkable strides in developing new treatments for rare blood disorders. The company’s latest quarterly report for Q2 2024 showcases impressive progress for several diseases: ▪️ …

OxyDial

Aug 16 2024

Eculizumab Shows Promise for Managing Transfusion Complications in Pediatric SCD Patients

New research suggests Alexion Pharmaceuticals, Inc.‘ immunosuppressive medication, eculizumab, may safely manage hyperhemolysis syndrome (HHS) in pediatric sickle cell disease patients. A Pediatric Blood & Cancer study reported that a …

OxyDial

Jul 25 2024

Emmaus Life Sciences, Inc complies with FDA safety regulations of Endari

Emmaus Life Sciences reports compliance with FDA postmarketing safety regulations for Endari, its sickle cell disease treatment. After a 2.5-day inspection under the FDA’s Postmarketing Adverse Drug Experience (PADE) program, …

OxyDial

Jul 19 2024

Novartis’ sickle cell disease drug candidate shows promise in animal studies

Novartis has reported encouraging results for its experimental SCD treatment, a “glue degrader” small molecule. In animal studies, the drug effectively increased fetal hemoglobin (HbF) levels, crucial for managing SCD …